Introduction
Somefemale gene carriers of Duchennemuscular dystrophy (DMD) show cardiac dysfunction in addition to skeletal muscle dysfunction (1) (2) (3) . Werecently reported (4) a high frequency of clinical and subclinical involvement of cardiac and skeletal muscles in female gene carriers of DMD. In this study, we measured the plasma levels of brain natriuretic peptide (BNP) (5-9) and atrial natriuretic peptide (ANP) (10, 1 1) to investigate the potential of using plasma BNPand ANPlevels as indices of cardiac dysfunction in female gene carriers of DMD. ANPis mainly released from atrial muscle cells into the blood in response to an increase in right or left atrial pressure (10, 12) . In contrast, BNPis synthesized in ventricular muscles in response to ventricular overload, and is secreted into the coronary sinuses and then into the blood (5, 12).
Patients and Methods
Fifteen female gene carriers of DMD, all of whomwere mothers of patients with DMDtreated as outpatients or inpatients at the National Sanatorium Tokushima Hospital, were studied. Their age ranged from 34 to 61 years (45.8 ± 8.0, mean ± SD). The diagnosis was based on finding deletions in the dystrophin gene by Southern blotting (13), mosaic staining of dystrophin in the muscle cells of skeletal muscle biopsy (14), highly elevated levels (more than 1,250 IU//) (normal range: < 1 25) of serum creatine kinase activity, or genetic confirmation of definite carrier based on the pedigree. Five subjects had mild cardiac symptoms such as palpitation and feeling ofprecordial compression, but there was no evident manifestation of cardiac failure such as orthopnea or edemain the lower limbs. All subjects had a normal blood pressure.
The cardiothoracic ratio (CTR) was estimated on chest roentgenogram, and the left ventricular end-diastolic dimension (LVDd) and fractional shortening (FS) were determined by echocardiographic examination. The correlations of plasma BNPand ANPlevels with the indices of cardiac function, CTR, LVDd, and FS, were studied, and statistically analyzed by the Mann-Whitney U-test using GB-STAT, version 4.0 (Dynamic Microsystem Inc., Silver Spring, USA). p<0.05 was considered as statistically significant.
The levels of plasma BNPand ANPwere determined by immunoradiometric assay using Shionoria ANP(15) and BNP (16) Kits (Shionogi Pharmaceutical Co., Osaka) according to
The objective of the investigation was explained to the subjects and informed consent was obtained from all of them.
Results
Plasma levels of BNPand ANP The levels of plasma BNP ranged from 4 to 57 pg/ml (22.1 ± 15.1, mean ± SD) (Fig. la) . The upper limit of the normal value of the plasma BNPlevel is 18.6 pg/ml, and there are no significant individual variations in this level in people aged 30 to 60 years (17). We found an elevated plasma BNP level in 8 (53%) of the 15 DMDcarriers. Four (50%) of these eight carriers with an elevated plasma BNPlevel had no cardiac symptoms. On the other hand, plasma ANPlevels ranged from 5 to 18 pg/ml (10.8 ± 3.8, mean ± SD), which were all normal ( cardiac symptoms improved, the BNPlevel decreased to 27 pg/ ml, LVDddecreased, and FS increased. There was no increase in the plasma ANPlevel throughout this period (Fig. 4) .
Discussion
The main causes of death in patients with DMD are respiratory failure and heart failure ( 19), which have been attributed to a deficiency of dystrophin in the skeletal muscle and in the myocardium (20, 21). Skeletal muscle weakness ( 1) and cardiac manifestations (2, 3) have been observed in some DMDfemale gene carriers, and these conditions are also believed to result from an abnormal expression of dystrophin in the skeletal muscle and in the myocardium(4). Cardiac dysfunction is one of the main causes of death in some female carriers (22) The positive correlation between age and the plasma BNP level indicates that older DMDcarriers have a greater load on the cardiac muscle. This finding highlights the importance of paying attention to cardiac function in older DMD carriers. In a DMD carrier whose cardiac function was followed for more than one year, the slightly elevated plasma BNPlevel that was found before the appearance of cardiac symptomsfurther increased after the development of symptoms, and then declined after treatment with an ACEinhibitor, which shows that ACEinhibitors are effective in reducing cardiac load and latent cardiac dysfunction. Cardiac dysfunction in DMD carriers has not received as muchattention as that in DMDpatients. However, the present results show that female gene carriers often exhibit cardiac dysfunction, including latent cardiac dysfunction. Therefore, we believe that long-term evaluation of the plasma BNPlevel maybe useful for detecting cardiac dysfunction and for estimating the efficacy of treatment in DMDcarriers.
